.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,100,901

« Back to Dashboard

Details for Patent: 5,100,901

Title: Cyclic amine compounds and pharmaceutical use
Abstract:A cyclic amine compound is defined by the formula: ##STR1## in which J is indanyl, indanonyl, indenyl, indenonyl, indanedionyl, tetralonyl, benzosuberonyl, indanolyl or a divalent group thereof, K is phenyl, an arylalkyl or cynnamyl, B is --(CHR22) r--, R22 being H or methyl, --CO-- (CHR22)r--, .dbd.(CH--CH.dbd.CH)b--, .dbd.CH--(CH2)c-- or .dbd.(CH--CH)d.dbd. and the ring including T and Q is piperidine. The compound is useful to treat senile dementia.
Inventor(s): Sugimoto; Hachiro (Ushiku, JP), Tsuchiya; Yutaka (Fort Lee, NJ), Higurashi; Kunizou (Tokyo, JP), Karibe; Norio (Tsukuba, JP), Iimura; Youichi (Tsukuba, JP), Sasaki; Atsushi (Tsukuba, JP), Yamanishi; Yoshiharu (Ryugasaki, JP), Ogura; Hiroo (Tsuchiura, JP), Araki; Shin (Tsukuba, JP), Kosasa; Takashi (Tsukuba, JP), Kubota; Atsuhiko (Tsukuba, JP), Kosasa; Michiko (Tsukuba, JP), Yamatsu; Kiyomi (Kamakura, JP)
Assignee: Eisai Co., Ltd. (Tokyo, JP)
Filing Date:Oct 18, 1989
Application Number:07/423,349
Claims:1. A cyclic amine compound having the following formula (XXV) or a pharmacologically acceptable salt thereof: ##STR325## in which J is a monovalent or divalent compound containing a phenyl group and selected from the group consisting of (1) indanyl, (2) indanonyl, (3) indenyl, (4) indenonyl, (5) indanedionyl, (6) tetralonyl, (7) benzosuberonyl, (8) indanolyl and (9) indanonylidenyl, said phenyl group optionally being substituted;

B is --(CHR.sup.22).sub.r --, --CO--(CHR.sup.22).sub.r --, --NR.sup.4 --(CHR.sup.22).sub.r --, R.sup.4 being hydrogen, a lower alkyl, an acyl, a lower alkylsulfonyl, phenyl or benzyl, --CO--NR.sup.5 --(CHR.sup.22).sub.r --, R.sup.5 being hydrogen, a lower alkyl or phenyl, --CH.dbd.CH--(CHR.sup.22).sub.r --, --OCOO--(CHR.sup.22).sub.r --, --OOC--NH--(CHR.sup.22).sub.r --, --NH--CO(CHR.sup.22).sub.r --, --CH.sub.2 --CO--NH--(CHR.sup.22).sub.r --, --(CH.sub.2).sub.2 --CO--NH--(CHR.sup.22).sub.r --, --CH(OH)--(CHR.sup.22).sub.r --, r being zero or an integer of 1 to 10, R.sup.22 being hydrogen or methyl, .dbd.(CH--CH.dbd.CH).sub.b --, b being an integer of 1 to 3, .dbd.CH--(CH.sub.2).sub.c --, c being zero or an integer of 1 to 9, .dbd.(CH--CH).sub.d .dbd., d being zero or an integer of 1 to 5; --CO--CH.dbd.CH--CH.sub.2 --, --CO--CH.sub.2 CH(OH)--CH.sub.2 --, --CH(CH.sub.3)--CO--NH--CH.sub.2 --, --CH.dbd.CH--CO--NH--(CH.sub.2).sub.2 --, --NH--, --O--, --S--, a dialkylaminoalkylcarbonyl or a lower alkoxycarbonyl;

T is carbon;

Q is nitrogen; and

q is 2;

K is hydrogen, phenyl, a substituted phenyl, an arylalkyl containing a phenyl group which may have a substituent, cinnamyl, a lower alkyl, pyridylmethyl, a cycloalkylalkyl, adamantanemethyl, furylmethyl, a cycloalkyl, a lower alkoxycarbonyl or an acyl group; and

shows a single bond or a double bond, with the proviso that J is not indanonyl when B is --(CHR.sup.22).sub.r --.

2. A cyclic amine compound having the following formula (XXV) or a pharmacologically acceptable salt thereof: ##STR326## in which J is a monovalent or divalent compound containing a phenyl group and selected from the group consisting of (1) indanyl, (2) indanonyl, (3) indenyl, (4) indenonyl, (5) indanedionyl, (6) tetralonyl, (7) benzosuberonyl, (8) indanolyl, and (9) indanonylidenyl, said phenyl group optionally being substituted;

B is --(CHR.sup.22).sub.r --, r being zero or an integer of 1 to 10, R.sup.22 being hydrogen or methyl, .dbd.(CH--CH.dbd.CH).sub.b --, b being an integer of 1 to 3, .dbd.CH--(CH.sub.2).sub.c --, c being zero or an integer of 1 to 9, .dbd.(CH--CH).sub.d .dbd., d being zero or an integer of 1 to 5;

Q is nitrogen, T is carbon and q is 2;

K is phenylalkyl or phenylalkyl which may have a substituent on the phenyl group, cinnamyl, a lower alkyl, pyridylmethyl, a cycloalkylalkyl, adamantanemethyl, furylmethyl, a cycloalkyl, a lower alkoxycarbonyl or an acyl group; and

indicates a single bond or a double bond, with the proviso that J is not indanonyl when B is --(CHR.sup.22).sub.r --.

3. A cyclic amine compound as claimed in claim 1 or a pharmacologically acceptable salt thereof, in which J is (b) selected from the group consisting of indanonyl, indenyl, indanedionyl and indanonylidenyl.

4. A cyclic amine compound as claimed in claim 1 or a pharmacologically acceptable salt thereof, in which B is --(CHR.sup.22).sub.r, .dbd.(CH--CH.dbd.CH).sub.b, .dbd.CH--(CH.sub.2).sub.c or .dbd.(CH--CH).sub.d.dbd..

5. A cyclic amine compound as claimed in claim 1 or a pharmacologically acceptable salt thereof, in which J is indanonyl and B is .dbd.(CH--CH.dbd.CH).sub.b, .dbd.CH--(CH.sub.2).sub.c -- or .dbd.(CH--CH).sub.d .dbd..

6. A cyclic amine compound as claimed in claim 1 or a pharmacologically acceptable salt thereof, which is selected from the group consisting of:

1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-ylidenyl)methylpiperidine,

1-cyclohexylmethyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine,

1-benzyl-4-((5,6-dimethoxy-1-oxoindanon)-2-yl)-propenylpiperidine.

7. A therapeutical composition which comprises a pharmacologically effective amount of the cyclic amine compound as defined in claim 1 or a pharmacologically acceptable salt thereof and a pharmacologically acceptable carrier.

8. A method for treating a disease accompanied by acetylcholinesterase activity by administering to a human patient an effective amount of the cyclic amine compound as defined in claim 1 or a pharmacologically acceptable salt thereof for inhibiting the acetylcholinesterase activity.

9. A method as claimed in claim 7, in which the disease is senile dementia.

10. A method as claimed in claim 7, in which the disease is senile dementia of the Alzheimer type.

11. A compound having the formula ##STR327## in which J is selected from the group consisting of ##STR328## in which t is an integer of 1 to 4 and S is selected from the group consisting of hydrogen, alkyl having 1 to 6 carbon atoms, alkoxy having 1 to 6 carbon atoms, and, when t is 2, (S).sub.t can be methylenedioxy or ethylenedioxy connected to two adjacent carbon atoms on the phenyl ring, B is selected from the group consisting of --(CHR.sup.22).sub.r --, --CH.dbd.CH--(CHR.sup.22).sub.r --, .dbd.(CH--CH.dbd.CH).sub.b, .dbd.CH--(CH.sub.2).sub.c -- and .dbd.(CH--CH).sub.d .dbd., R.sup.22 is hydrogen or methyl, r is zero or an integer of 1 to 10, b is an integer of 1 to 3, c is zero or an integer of 1 to 9 and d is zero or an integer of 1 to 5:

K is hydrogen, phenyl, substituted phenyl, phenylalkyl, phenylalkyl having a substituent on the phenyl ring, cinnamyl, lower alkyl, pyridylmethyl, cycloalkylalkyl, adamantanemethyl, furylmethyl, cycloalkyl, alkoxycarbonyl or acyl; and

indicates a single bond or a double bond, with the proviso that J is not ##STR329## when B is --(CHR.sup.22).sub.r --, or a pharmacologically acceptable salt thereof.

12. A compound having the formula ##STR330## wherein c is zero or an integer of 1 to 9, S is hydrogen or a substituent on the phenyl ring, and t is an integer of 1 to 4, with the proviso that (S).sub.t can be a methylenedioxy group or an ethylenedioxy group joined to two adjacent carbon atoms of the phenyl ring; and

K is hydrogen, phenyl, substituted phenyl, phenylalkyl, phenylalkyl having a substituent on the phenyl ring, cinnamyl, lower alkyl, pyridylmethyl, cycloalkylalkyl, adamantanemethyl, furylmethyl, cycloalkyl, alkoxycarbonyl or acyl,

or a pharmacologically acceptable salt thereof.

13. A compound having the formula ##STR331## wherein t is an integer of 1 to 4, and S is selected from the group consisting of hydrogen, alkyl having 1 to 6 carbon atoms, alkoxy having 1 to 6 carbon atoms, and, when t is 2, (S).sub.t can be methylenedioxy or ethylenedioxy connected to two adjacent carbon atoms on the phenyl ring, or a pharmacologically acceptable salt thereof.

14. A compound having the formula ##STR332## wherein J is ##STR333## t is an integer of 1 to 4 and S is selected from the group consisting of hydrogen, alkyl having 1 to 6 carbon atoms, alkoxy having 1 to 6 carbon atoms, and, when t is 2, (S).sub.t can be methylenedioxy or ethylenedioxy connected to two adjacent carbon atoms on the phenyl ring;

when J is ##STR334## B is --CH.dbd.CH--(CHR.sup.22).sub.r 13 wherein r is zero or an integer of 1 to 10 and R.sup.22 is hydrogen or methyl, and when J is ##STR335## B is selected from the group consisting of .dbd.(CH--CH.dbd.CH).sub.b -- wherein b is an integer of 1 to 3, .dbd.CH--(CH.sub.2).sub.c -- wherein c is zero or an integer of 1 to 9 or .dbd.(CH--CH).sub.d -- wherein d is zero or an integer of 1 to 5; and K is selected from the group consisting of phenyl, substituted phenyl, arylalkyl, ring-substituted arylalkyl, alkylcycloalkyl, cinnamyl, benzoyl and ring-substituted benzoyl,

indicates a single or double bond, or a pharmacologically acceptable salt thereof.

15. A compound as claimed in claim 14 in which K is benzyl.

16. A compound as claimed in claim 15 in which B is .dbd.CH--(CH.sub.2).sub.c and J is ##STR336##

17. A compound as claimed in claim 14, which is 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-ylidenyl]-methylpiperidine or pharmacologically acceptable salt thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc